8I

Syneos Health IncMUN Syneos Stock Report

Last reporting period 30 Jun, 2023

Updated —

Last price

Market cap $B

4.458

Middle

Exchange

XMUN - Boerse Muenchen

8IN.MU Stock Analysis

8I

Uncovered

Syneos Health Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

28/100

Low score

Market cap $B

4.458

Dividend yield

Shares outstanding

103.24 B

Syneos Health, Inc. engages in the provision of biopharmaceutical solutions. The company is headquartered in Morrisville, North Carolina and currently employs 28,768 full-time employees. The company went IPO on 2014-11-07. The firm operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company’s customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.

View Section: Eyestock Rating